Helicobacter pylori infection in children. (September 2017)

• Record Type: Journal Article
• Authors: Kalach, Nicolas; Bontems, Patrick; Raymond, Josette
• Other Names: Mégraud Francis guestEditor.; Malfertheiner Peter guestEditor.
• Is Part Of: Helicobacter. Volume 22(2017) Supplement 1
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-09
• Subjects: antimicrobial resistance -- diagnosis -- epidemiology -- gastric microbiota -- treatment -- vaccine; Helicobacter -- Periodicals; Helicobacter infections -- Periodicals; Stomach -- Diseases -- Periodicals; 616.3301405
• DOI: 10.1111/hel.12414
• Languages: English
• ISSNs: 1083-4389

Abstract

Abstract: Helicobacter pylori infection in children differs from that in adults, from the point of view of epidemiology, host response, clinical features, related diseases, and diagnosis, as well as treatment strategies. The prevalence of H. pylori infection, in both children and adults, is decreasing in the Western World as well as in some developing countries, which contrasts with the increase in childhood asthma and allergic diseases. Recurrent abdominal pain is not specific during H. pylori infection in children. The role of H. pylori infection and failure to thrive, children's growth, type I diabetes mellitus (T1DM) and celiac disease remains controversial. The main initial diagnosis is based on upper digestive endoscopy with biopsy‐based methods. Nodular gastritis may be a pathognomonic endoscopic finding of childhood H. pylori infection. The infection eradication control is based on validated noninvasive tests. The main cause of treatment failure of H. pylori infection is its clarithromycin resistance. We recommend standard antibiotic susceptibility testing of H. pylori in pediatric patients prior to the initiation of eradication therapy. H. pylori treatment in children should be based on an evaluation of the rate of eradication in the local population, a systematic use of a treatment adapted to the susceptibility profile and a treatment compliance greater than 90%. The last meta‐analysis in children did not show an advantage for sequential therapy when compared to a 14‐day triple therapy. Finally, the high rate of antibiotic resistance responsible for therapy failure in recent years justifies the necessity of a novel vaccine to prevent H. pylori infection in children.